Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 8:14:1359432.
doi: 10.3389/fcimb.2024.1359432. eCollection 2024.

Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go

Jian-Xiu Yu  1 , Xin Chen  1 , Su-Gang Zang  1 , Xi Chen  1 , Yan-Yan Wu  1 , Li-Pei Wu  1 , Shi-Hai Xuan  1
Affiliations
Review

Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go

Jian-Xiu Yu et al. Front Cell Infect Microbiol. .

Abstract

Diabetic nephropathy (DN) is one of the main complications of diabetes and a major cause of end-stage renal disease, which has a severe impact on the quality of life of patients. Strict control of blood sugar and blood pressure, including the use of renin-angiotensin-aldosterone system inhibitors, can delay the progression of diabetic nephropathy but cannot prevent it from eventually developing into end-stage renal disease. In recent years, many studies have shown a close relationship between gut microbiota imbalance and the occurrence and development of DN. This review discusses the latest research findings on the correlation between gut microbiota and microbial metabolites in DN, including the manifestations of the gut microbiota and microbial metabolites in DN patients, the application of the gut microbiota and microbial metabolites in the diagnosis of DN, their role in disease progression, and so on, to elucidate the role of the gut microbiota and microbial metabolites in the occurrence and prevention of DN and provide a theoretical basis and methods for clinical diagnosis and treatment.

Keywords: diabetic nephropathy; diagnosis and treatment; gut microbiota; microbial metabolites; therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Gut microbiota associated with development of DN. (By Figdraw).
Figure 2
Figure 2
Metabolism associated with development of DN. (By Figdraw).
Figure 3
Figure 3
The management and therapeutic strategies of DN based on gut microbiota. (By Figdraw).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Żółkiewicz J., Marzec A., Ruszczyński M., Feleszko W. (2020). Postbiotics-A step beyond pre-and probiotics. Nutrients 12, 2189. doi: 10.3390/nu12082189 - DOI - PMC - PubMed
    1. Balint L., Socaciu C., Socaciu A. I., Vlad A., Gadalean F., Bob F., et al. . (2023). Quantitative, targeted analysis of gut microbiota derived metabolites provides novel biomarkers of early diabetic kidney disease in type 2 diabetes mellitus patients. Biomolecules 13, 1086. doi: 10.3390/biom13071086 - DOI - PMC - PubMed
    1. Bian J., Liebert A., Bicknell B., Chen X. M., Huang C., Pollock C. A. (2022). Faecal microbiota transplantation and chronic kidney disease. Nutrients 14, 2528. doi: 10.3390/nu14122528 - DOI - PMC - PubMed
    1. Bock P. M., Telo G. H., Ramalho R., Sbaraini M., Leivas G., Martins A. F., et al. . (2021). The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 64, 26–41. doi: 10.1007/s00125-020-05295-1 - DOI - PubMed
    1. Cai K., Ma Y., Cai F., Huang X., Xiao L., Zhong C., et al. . (2022). Changes of intestinal microbiota in diabetic nephropathy and its effect on the progression of kidney injury. Endocrine 76, 294–303. doi: 10.1007/s12020-022-03002-1 - DOI - PubMed